People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Plus Therapeutics, Inc. | — | Pharmaceuticals | Series A | $4.6M | $9.3M | 2009 |
Mark E Saad at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark E Saad on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard J. Hawkins | 1 | 4 |
| Ronald D Henriksen | 1 | 2 |
| E Carmack Holmes, MD | 1 | 1 |
| David M Rickey | 1 | 1 |
| Paul W Hawran | 1 | 1 |
| Christopher J Calhoun | 1 | 1 |
| Robert J. Lenk | 1 | 1 |
| Greg J. Petersen | 1 | 1 |
| Howard H. Clowes | 1 | 1 |
| Andrew H. Sims | 1 | 1 |
| An H. Van Es-Johansson | 1 | 1 |
| Marc H Hedrick | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.